Globus Medical Inc (GMED) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Globus Medical Inc   (NYSE: GMED)


Globus Medical Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Globus Medical Inc 's ROA in the second quarter of 2026?
Globus Medical Inc achieved a return on average assets (ROA) of 9.82 % in its second quarter of 2026, which is below Globus Medical Inc 's average return on assets, which stands at 10.29%.

ROA fell compared to the first quarter of 2026, despite the net income growth of 21.94% from the first quarter of 2026.

However, within the Healthcare sector 97 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 543, from total ROA ranking in the first quarter of 2026 at 642.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 18.83 % 15.46 % 5.18 % 2.07 % 0.73 %
Y / Y Net Income Change -25.28 % 64.72 % 430.44 % 129.5 % 538.68 %
Net Income (TTM) in million 535 587 538 424 357
Return On Assets (TTM) 9.82 % 11.24 % 10.68 % 8.53 % 7.21 %
GMED's Total Ranking # 543 # 642 # 722 # 883 # 1424
Total Assets (TTM) in million 5,895 5,440 5,375 5,096 4,961
Seq. Total Assets Change 8.38 % 1.21 % 5.47 % 2.71 % 5.31 %
Seq. Net Income Change 21.94 % -11.59 % 18.18 % -41.35 % 168.81 %

GMED's 5 Years Annual ROA >> Back to GMED Management Effectiveness >> Compare GMED ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 27
Sector # 98
Overall # 601

Return On Assets Statistics
High Average Low
18.93 %
10.29 %
0.8 %
(Dec 31 2012)   (Jun 30 2024)



  News about Globus Medical Inc Return on Assets ROA

A New Epoch in Medical Innovation Globus Medical Inc. Unveils the ADIRA XLIF Plate System Amidst Financial Variances,...

Globus Medical Heralds New Dawn with ADIRA XLIF Plate SystemIn an age where the boundaries of scientific and medical ingenuity seem ever-expansive, it is with great anticipation and fanfare that we herald the advent of Globus Medical Inc. s latest innovation the ADIRA XLIF Plate System. The esteemed establishment, a paragon in the realm of musculoskeletal solutions, announced their commercial launch on the 21st of August in the year of Our Lord, 2024. This unveiling marks a significant milestone, being the Company s inaugural product launch that aligns seamlessly with its broadened lateral interbody portfolio.Situated in the bucolic yet industrious precincts of Audubon, Pennsylvania, Globus Medical Inc. (NYSE: GMED) has long stood as a bastion of pioneering health solutions. However, the financial nuances of their recent quarterly performances paint a portrait that mingles triumphs with trials.



Financial Statements
Globus Medical Inc 's Assets $ 5,895 million GMED's Balance sheet
Globus Medical Inc 's Income $ 152 million Quarterly GMED's Income Statement
GMED's Income by Division See GMED's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 5.18 % 1.79 % 141.46 % 6.22 % 16.54 %
Total Assets in million 5,375 5,110 5,020 2,079 1,957
Y / Y Net Income Change 422.28 % -16.19 % -35.39 % 27.47 % 45.86 %
Net Income in million 538 103 123 190 149
Annual Return On Assets 10.01 % 2.02 % 2.45 % 9.15 % 7.62 %

GMED's 5 Years Annual ROA >> Back to GMED Management Effectiveness >> Compare GMED ROA to its Competitors



Comment on GMED's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 10.01 % compared to prior year, due to annual net income growth of 422.28 % to $537.87 million, while value of Globus Medical Inc 's overall assets grew just by 5.18 % to $5,374.58 million, compared to $5,374.58 a year before.


More Return On Assets Ratios
GMED's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GMED's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GMED's Competitors
Subscribers only: Roa for Globus Medical Inc 's Suppliers
Subscribers only: Return On Assets for GMED's Customers

You may also want to know
GMED's Roi GMED's Inventory Turnover Ratio GMED's Growth Rates GMED's Dividend Comparisons
GMED's Profitability Ratios GMED's Asset Turnover Ratio GMED's Dividend Growth
GMED's Roe GMED's Valuation Ratios GMED's Financial Strength Ratios GMED's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %
Standard Biotools Inc   14.31 %
Arcutis Biotherapeutics Inc   14.23 %
Harmony Biosciences Holdings inc   14.15 %

Date modified: 2026-09-08T17:55:39+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.